Ph.D. Program




Members > Thomas Bayer

Last update:


Thomas Bayer

Professor of Molecular Psychiatry

  • 1993 Postdoctoral Research Fellow, University of Cologne, Cologne, Germany (Prof. J.A. Campos-Ortega)

  • 1993-1997 Postdoctoral Research Fellow, Institute of Neuropathology (Prof. O. Wiestler), University of Bonn Medical Center, Bonn, Germany

  • 1997-2002 Lab leader, Department of Psychiatry (Prof. P. Falkai), University of Bonn Medical Center, Bonn, Germany

  • 2002-2007 Head of Neurobiology Lab, University of Saarland Medical Center, Homburg, Germany

  • 2004 Appointment to apl Professor at the University Medical Center Saarland

  • 2007-present W2 Professor in Molecular Psychiatry at the University Medicine Göttingen, Department of Psychiatry

  • Since 2006 Coordinator of the European Commission funded International Alzheimer PhD School «Neurodegeneration in Alzheimer’s disease – mechanism, consequence and therapy» (NEURAD).

Major Research Interests:

Thomas Bayer

Pathogenesis of Alzheimer´s disease, neuronal cell death mechanisms, preclinical proof-of-concept studies; characterization and development of mouse models for Alzheimer´s disease (neuropathology, anatomy, biochemistry, behavioural tests), preclinical therapy studies in mouse models, blood and CSF biomarker analysis, coordination and design of a phase II clinical study with Alzheimer´s disease patients (
Research Group / NEURAD graduate school

Dept. of Psychiatry
Div. of Molecular Psychiatry
von-Siebold-Straße 5
37075 Göttingen

phone:+49-551-39 22912
fax:+49-551-39 10291

Further Information:
Dept. of Psychiatry

Selected Recent Publications:

Bayer TA, Schäfer S, Simons A, Kemmling, Kamer T, Tepest R, Eckert A, Schüssel K, Eikenberg O, Sturchler-Pierrat, Abramowski D, Staufenbiel, Multhaup G (2003) Dietary Cu stabilizes brain SOD-1 activity and reduces amyloid Aß production in APP23 transgenic mice. PNAS: 100:14187-14192

Casas C, Sergeant N, Itier J-M, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aß42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165(4):1289-1300

Schmitz C, Rutten BPF, Pielen A, Schäfer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Korr H, Steinbusch HWM, Pradier L, Bayer TA (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164:1495-1502

Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, Multhaup G (2004). Clioquinol Mediates Copper Uptake and Counteracts Copper Efflux Activities of the Amyloid Precursor Protein of Alzheimer's Disease. J. Biol. Chem. 279 (50):51958-51964

Kessler H, Pajonk F-G, Meisser P, Schneider-Axman T, Hoffmann K-H, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J. Neural Transm. 113:1763-1769

Wirths O, Weis J, Kayed R, Saido T, Bayer TA (2007) Age-dependent axonal degeneration in an Alzheimer mouse model Neurobiol. Aging, 28 (2007) 1689'1699

Wirths O, Breyhan H, Schäfer S, Roth C, Bayer TA (2008) Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging 891-901

Christensen DZ, Flohr JCA, Kraus SL, Cotel M-C, Wirths O and Bayer TA (2008) Transient intraneuronal Aß (and not plaques) correlates with loss of frontal cortical neurons in APP/PS1KI mice. Acta Neuropathol. 116:647-655